Track market-moving stories before they get noisy

Tenet Healthcare Corporation (THC) Q2 2026 Earnings Call Transcript

Top Analyst-Rated Healthcare Stocks to Watch NowTenet Healthcare NYSE: THC raised its full-year 2026 financial outlook after reporting second-quarter results that exceeded its expectations, supported by hospital volume growth, higher-acuity services, expense-management efforts and continued strength in its ambulatory surgery business.

Second-quarter net operating revenues totaled $5.6 billion, while consolidated adjusted EBITDA rose 16.3% from a year earlier to $1.304 billion. Adjusted EBITDA margin was 23.2%, and adjusted diluted earnings per share increased 52% year over year to $6.12.

Get Tenet Healthcare alerts:

3 Under-the-Radar Healthcare CompaniesChairman and Chief Executive Officer Dr. Saum Sutaria said the company’s first-half fundamental outperformance totaled approximately $97 million across its operating segments. “Hospital volumes and same-store revenue growth in both segments are strong,” Sutaria said, adding that margin performance benefited from technology-enabled expense initiatives implemented at the beginning of the year.

Guidance Raised for Revenue, EBITDA and Cash Flow For 2026, Tenet increased its consolidated net operating revenue outlook to a range of $21.9 billion to $22.5 billion, representing a $300 million increase at the midpoint from its previous forecast. The company raised adjusted EBITDA guidance to $4.83 billion to $5.03 billion, a $295 million increase at the midpoint.

HCA Healthcare: Temporary Setbacks, Long-Term StrengthManagement said the revised EBITDA outlook reflects roughly $100 million in fundamental outperformance during the first half and another $60 million from the expected continuation of those drivers in the second half. The company also cited contributions from ambulatory surgery acquisitions and supplemental Medicaid programs.

Adjusted free cash flow after noncontrolling interests is now projected at $1.825 billion to $2.055 billion, up $225 million at the midpoint. That outlook includes roughly $150 million of tax payments related to the Conifer transaction. Excluding those payments, the midpoint would be approximately $2.1 billion, Chief Financial Officer Sun Park said.

Hospital Segment Outperforms Despite Exchange Pressure Tenet’s hospital segment generated $762 million in adjusted EBITDA, up 22% from the second quarter of 2025, with an 18% adjusted EBITDA margin. Same-hospital inpatient adjusted admissions increased 2.6%, while revenue per adjusted admission rose 3.3% year over year.

Park said the revenue-per-admission increase reflected the company’s acuity strategy and higher supplemental Medicaid revenue, partly offset by lower exchange volumes. The company recognized $92 million of favorable out-of-period supplemental Medicaid revenue tied to prior years, compared with $70 million in the prior-year quarter. Park said Tenet would have recorded a “clean beat” even without the incremental Medicaid revenue.

Exchange revenue declined 17% from the second quarter of 2025 and accounted for about 5.5% of consolidated revenue during the quarter. Exchange admissions fell about 13.5%, according to Park, resulting in an approximately $65 million revenue headwind.

Management said the exchange decline was most pronounced in Florida, Arizona, Michigan, South Carolina and Texas. Park said the company saw exchange patients shift to uninsured status at a rate that was “pretty much one-to-one,” with uninsured volume increasing proportionately in the second quarter.

Tenet expects the exchange-market trends seen in the second quarter to continue through the rest of 2026 and did not change its assumptions for the back half of the year. Sutaria said the company has been adjusting its cost base while maintaining investments in growth initiatives.

USPI Emphasizes Higher-Acuity Procedures United Surgical Partners International, Tenet’s ambulatory surgery business, reported adjusted EBITDA of $542 million, an 8.8% increase from the prior-year quarter. Its adjusted EBITDA margin was 39%.

USPI same-facility systemwide revenue rose 5%, including a 6.3% increase in net revenue per case. Same-facility case volume declined 1.2%, which management attributed to its focus on higher-acuity care and the migration of lower-acuity procedures to office settings.

Sutaria highlighted 10% year-over-year same-store growth in total joint replacements at the company’s ambulatory surgery centers. He said USPI continues to expand into higher-acuity orthopedic procedures as well as urology, robotics, bariatrics and cardiovascular services. The company is also pursuing more complex procedures in established gastrointestinal and ophthalmology service lines.

Tenet now expects to spend more than $300 million on ambulatory surgery center mergers and acquisitions during 2026, reflecting transactions completed so far and its current pipeline of opportunities.

Cost Management and Capital Deployment In response to analyst questions, Sutaria outlined several components of Tenet’s cost-management strategy. These include traditional productivity measures, renegotiating purchased-service contracts and supply standardization, as well as clinical operating improvements involving length of stay, emergency department service levels, hospital throughput and operating-room and catheterization-lab scheduling.

The company is also using automation, artificial intelligence and its global business center to improve productivity and automate certain functions across payment operations and support structures, Sutaria said.

Tenet generated $444 million in adjusted free cash flow during the second quarter and $1.422 billion year to date. As of June 30, it had $2.17 billion of cash on hand, no outstanding borrowings under its revolving credit facility and no significant debt maturities until late 2027.

The company repurchased 5.7 million shares for $1.04 billion during the second quarter. First-half share repurchases totaled nearly 7 million shares, costing $1.36 billion. Tenet’s board authorized a further $2 billion increase to its share repurchase program, and management said it expects to remain active in buybacks through the remainder of the year.

Tenet reported a leverage ratio of 2.33 times EBITDA as of June 30, or 2.9 times EBITDA excluding noncontrolling interests. Management said capital priorities include ambulatory surgery acquisitions, hospital investments focused on higher-acuity services, share repurchases and potential debt retirement or refinancing.

About Tenet Healthcare (NYSE:THC)Tenet Healthcare Corporation NYSE: THC is a diversified American healthcare services company that owns and operates acute care hospitals and a broad range of outpatient facilities. Its portfolio includes general acute-care hospitals, specialty hospitals, ambulatory surgery centers, urgent care and diagnostic imaging centers, and other ancillary service locations. Tenet's operations are oriented around delivering inpatient and outpatient clinical care across multiple medical specialties, with an emphasis on surgical services, emergency care, and advanced diagnostics.

In addition to facility-based care, Tenet provides integrated services designed to support clinical operations and improve patient access and care coordination.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in Tenet Healthcare Right Now?Before you consider Tenet Healthcare, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tenet Healthcare wasn't on the list.

While Tenet Healthcare currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Tenet Healthcare (THC - Free Report) came out with quarterly earnings of $6.12 per share, beating the Zacks Consensus Estimate of $4.08 per share. This compares to earnings of $4.02 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +50.00%. A quarter ago, it was expected that this hospital operator would post earnings of $4.21 per share when it actually produced earnings of $4.82, delivering a surprise of +14.49%.

Over the last four quarters, the company has surpassed consensus EPS estimates four times.

Tenet, which belongs to the Zacks Medical - Hospital industry, posted revenues of $5.63 billion for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 4.40%. This compares to year-ago revenues of $5.27 billion. The company has topped consensus revenue estimates three times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Tenet shares have lost about 1.7% since the beginning of the year versus the S&P 500's gain of 9.6%.

What's Next for Tenet?While Tenet has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Tenet was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $4.22 on $5.47 billion in revenues for the coming quarter and $17.50 on $22.01 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Hospital is currently in the bottom 10% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Acadia Healthcare (ACHC - Free Report) , another stock in the same industry, has yet to report results for the quarter ended June 2026. The results are expected to be released on July 28.

This provider of inpatient behavioral health care services is expected to post quarterly earnings of $0.33 per share in its upcoming report, which represents a year-over-year change of -60.2%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Acadia Healthcare's revenues are expected to be $844.75 million, down 2.8% from the year-ago quarter.

DALLAS--(BUSINESS WIRE)--Tenet Healthcare Corporation (Tenet) (NYSE: THC) today announced its results for the quarter ended June 30, 2026. "Strong same-store revenue growth and effective expense management drove our fundamental outperformance in the second quarter of 2026 compared to our original assumptions," said Saum Sutaria, M.D., Chairman and Chief Executive Officer of Tenet. "We are actively navigating current industry dynamics through excellent operational execution, investments in innov.

Posted by Defense World Staff on Jul 23rd, 2026

Shares of Tenet Healthcare Corporation (NYSE:THC – Get Free Report) have been given an average recommendation of “Moderate Buy” by the twenty-one research firms that are currently covering the stock, MarketBeat Ratings reports. Four investment analysts have rated the stock with a hold recommendation and seventeen have given a buy recommendation to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $244.8421.

Several research analysts have recently issued reports on the stock. Weiss Ratings cut shares of Tenet Healthcare from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, June 2nd. TD Cowen cut their price target on shares of Tenet Healthcare from $242.00 to $233.00 and set a “buy” rating on the stock in a report on Monday, June 22nd. Morgan Stanley set a $254.00 price objective on shares of Tenet Healthcare in a research note on Friday, May 1st. Stephens dropped their target price on shares of Tenet Healthcare from $275.00 to $260.00 and set an “overweight” rating for the company in a report on Monday, May 4th. Finally, Wells Fargo & Company boosted their price target on Tenet Healthcare from $213.00 to $231.00 and gave the company an “overweight” rating in a report on Monday, July 13th.

View Our Latest Report on Tenet Healthcare

Insider Activity at Tenet Healthcare In other news, Director Nadja West sold 3,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 27th. The stock was sold at an average price of $177.35, for a total transaction of $532,050.00. Following the transaction, the director directly owned 24,805 shares of the company’s stock, valued at approximately $4,399,166.75. The trade was a 10.79% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director J Robert Kerrey sold 5,638 shares of the firm’s stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $174.52, for a total value of $983,943.76. Following the completion of the sale, the director directly owned 16,804 shares of the company’s stock, valued at $2,932,634.08. The trade was a 25.12% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.97% of the stock is currently owned by insiders.

Institutional Trading of Tenet Healthcare Institutional investors and hedge funds have recently bought and sold shares of the stock. Triumph Capital Management purchased a new position in shares of Tenet Healthcare during the 3rd quarter worth approximately $25,000. Activest Wealth Management bought a new stake in shares of Tenet Healthcare during the fourth quarter valued at approximately $26,000. Elyxium Wealth LLC purchased a new stake in Tenet Healthcare in the fourth quarter worth $29,000. Meeder Asset Management Inc. lifted its position in Tenet Healthcare by 146.2% during the fourth quarter. Meeder Asset Management Inc. now owns 192 shares of the company’s stock valued at $38,000 after buying an additional 114 shares during the period. Finally, Canada Pension Plan Investment Board bought a new stake in shares of Tenet Healthcare during the 2nd quarter valued at $35,000. 95.44% of the stock is currently owned by hedge funds and other institutional investors.

Tenet Healthcare Stock Down 0.3% Shares of NYSE:THC opened at $195.84 on Thursday. The stock has a market capitalization of $16.87 billion, a P/E ratio of 10.18, a price-to-earnings-growth ratio of 1.63 and a beta of 1.27. The stock’s 50-day moving average price is $184.41 and its 200-day moving average price is $197.37. The company has a current ratio of 1.36, a quick ratio of 1.30 and a debt-to-equity ratio of 1.96. Tenet Healthcare has a 12-month low of $146.60 and a 12-month high of $247.21.

Tenet Healthcare (NYSE:THC – Get Free Report) last issued its earnings results on Thursday, April 30th. The company reported $4.82 earnings per share for the quarter, beating the consensus estimate of $4.21 by $0.61. Tenet Healthcare had a return on equity of 25.55% and a net margin of 7.94%.The company had revenue of $5.37 billion during the quarter, compared to analysts’ expectations of $5.39 billion. During the same period in the prior year, the business posted $4.36 EPS. Tenet Healthcare’s quarterly revenue was up 2.6% compared to the same quarter last year. Tenet Healthcare has set its FY 2026 guidance at 16.380-18.68 EPS. On average, equities analysts anticipate that Tenet Healthcare will post 17.5 earnings per share for the current year.

About Tenet Healthcare (Get Free Report)

Tenet Healthcare Corporation (NYSE: THC) is a diversified American healthcare services company that owns and operates acute care hospitals and a broad range of outpatient facilities. Its portfolio includes general acute-care hospitals, specialty hospitals, ambulatory surgery centers, urgent care and diagnostic imaging centers, and other ancillary service locations. Tenet’s operations are oriented around delivering inpatient and outpatient clinical care across multiple medical specialties, with an emphasis on surgical services, emergency care, and advanced diagnostics.

In addition to facility-based care, Tenet provides integrated services designed to support clinical operations and improve patient access and care coordination.

See Also Five stocks we like better than Tenet Healthcare Could Truth API Become Trump Media’s First Meaningful Revenue Driver? Small Caps Are Crushing the S&P 500—3 Stocks Still Worth Buying Moog Is More Than a Missile Maker, and Wall Street Is Noticing A Boring Dividend Growth Strategy Becomes a Solid Defensive Play

Receive News & Ratings for Tenet Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenet Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEShake Shack, Inc. (NYSE:SHAK) Receives Average Rating of “Hold” from Brokerages

NEXT HEADLINE »Essex Property Trust, Inc. (NYSE:ESS) Receives Consensus Rating of “Moderate Buy” from Brokerages

Key Takeaways Tenet Healthcare reports Q2 results on July 24, with estimates calling for 1.5% EPS and 2.3% revenue growth.THC's Ambulatory Care business is expected to benefit from same-facility revenue growth and acquisitions.Tenet Healthcare faces pressure from lower patient days, shorter stays and higher costs. Hospital operator Tenet Healthcare Corporation (THC - Free Report) is set to report second-quarter 2026 results on July 24, 2026, before the opening bell. The Zacks Consensus Estimate for the to-be-reported quarter’s earnings is currently pegged at $4.08 per share on revenues of $5.39 billion. 

The second-quarter earnings estimate has decreased 3 cents over the past 60 days. Yet, the bottom-line projection indicates a year-over-year increase of 1.5%. Also, the Zacks Consensus Estimate for quarterly revenues suggests year-over-year growth of 2.3%.

Image Source: Zacks Investment Research

For full-year 2026, the Zacks Consensus Estimate for Tenet Healthcare’s revenues is pegged at $21.98 billion, implying a rise of 3.1% year over year. The consensus mark for 2026 earnings per share is pegged at $17.50, indicating a jump of 4.3% on a year-over-year basis.

Tenet Healthcare beat the consensus estimate for earnings in each of the trailing four quarters, with the average surprise being 20.6%, as you can see below.

Q2 Earnings Whispers for THCHowever, our proven model does not conclusively predict an earnings beat for the company this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold) increases the odds of an earnings beat. That’s not the case here.

THC has an Earnings ESP of 0.00% and carries a Zacks Rank #4 (Sell). You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.

What’s Shaping THC’s Q2 Results?The Zacks Consensus Estimate for adjusted patient admissions in total hospital operations suggests a 2.2% year-over-year decline. However, on the same hospital basis, the consensus estimate for adjusted patient admissions indicates a 1% increase from a year ago. The consensus mark for net patient revenues per adjusted admission in the second quarter signals a 10.2% year-over-year increase.

Meanwhile, the Ambulatory Care business is likely to have gained from strong growth in consolidated same-facility net patient service revenues, contributions from facility acquisitions and an expansion of service lines. Our model estimate for the Ambulatory Care segment’s net operating revenues suggests 7.8% growth from the prior-year quarter’s figure, whereas the consensus estimate indicates an 8.4% increase. The Zacks Consensus Estimate for adjusted EBITDA from Ambulatory Care operations suggests 5.1% year-over-year growth.

The Zacks Consensus Estimate for Hospital Operations and Services revenues for the second quarter is pegged at just a little over $4 billion, indicating a 0.1% increase from the year-ago period. However, the Zacks Consensus Estimate for adjusted EBITDA from the segment suggests a 2.8% year-over-year fall.

Both the consensus estimate and our model estimate suggest that second-quarter total hospital patient days have decreased 3% year over year. Both the Zacks Consensus Estimate and our model estimate for the average length of stay in total hospital indicate a 0.2% decrease from a year ago. Also, with increased utilization, costs are expected to have increased in the second quarter, making an earnings beat uncertain.

Stocks That Warrant a LookWhile an earnings beat looks uncertain for Tenet Healthcare, here are some companies from the broader Medical space that you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this time around:

ProMIS Neurosciences, Inc. (PMN - Free Report) has an Earnings ESP of +13.30% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.

The Zacks Consensus Estimate for ProMIS’ bottom line for the to-be-reported quarter of a loss of $1.45 indicates an 80% year-over-year improvement. It has witnessed one upward revision against no downward movement over the past 60 days.

Alcon Inc. (ALC - Free Report) has an Earnings ESP of +3.13% and a Zacks Rank of 2.

The Zacks Consensus Estimate for Alcon’s bottom line for the to-be-reported quarter indicates a 1.3% increase from a year ago. The company’s earnings beat estimates in three of the trailing four quarters and missed once, with an average surprise of 3.7%. The consensus estimate for ALC’s revenues is pegged at $2.77 billion, signaling a 7.3% increase.

Cardinal Health, Inc. (CAH - Free Report) has an Earnings ESP of +1.24% and a Zacks Rank of 2.

The Zacks Consensus Estimate for Cardinal Health’s bottom line for the to-be-reported quarter suggests 16.4% year-over-year growth. Its earnings beat estimates in each of the past four quarters, with an average surprise of 10.3%. CAH’s revenues for the to-be-reported quarter are pegged at $65.61 billion, a 9.1% increase from the year-ago period.

Tenet Healthcare (THC - Free Report) ended the recent trading session at $194.91, demonstrating a -2.15% change from the preceding day's closing price. This change lagged the S&P 500's 1.01% loss on the day. Meanwhile, the Dow lost 0.77%, and the Nasdaq, a tech-heavy index, lost 1.4%.

Coming into today, shares of the hospital operator had gained 15.43% in the past month. In that same time, the Medical sector gained 5.37%, while the S&P 500 gained 0.32%.

The investment community will be closely monitoring the performance of Tenet Healthcare in its forthcoming earnings report. The company is scheduled to release its earnings on July 24, 2026. The company is forecasted to report an EPS of $4.08, showcasing a 1.49% upward movement from the corresponding quarter of the prior year. Our most recent consensus estimate is calling for quarterly revenue of $5.39 billion, up 2.27% from the year-ago period.

THC's full-year Zacks Consensus Estimates are calling for earnings of $17.5 per share and revenue of $21.98 billion. These results would represent year-over-year changes of +4.29% and +3.13%, respectively.

Investors should also note any recent changes to analyst estimates for Tenet Healthcare. Recent revisions tend to reflect the latest near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.

Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.

Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.61% lower. At present, Tenet Healthcare boasts a Zacks Rank of #3 (Hold).

From a valuation perspective, Tenet Healthcare is currently exchanging hands at a Forward P/E ratio of 11.38. This expresses no noticeable deviation compared to the average Forward P/E of 11.38 of its industry.

Meanwhile, THC's PEG ratio is currently 1.65. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. The Medical - Hospital industry had an average PEG ratio of 1.65 as trading concluded yesterday.

The Medical - Hospital industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 102, finds itself in the top 42% echelons of all 250+ industries.

The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.

Tenet Healthcare (THC - Free Report) closed the most recent trading day at $204.25, moving -1.22% from the previous trading session. This change lagged the S&P 500's 0.42% gain on the day. Meanwhile, the Dow experienced a rise of 0.29%, and the technology-dominated Nasdaq saw an increase of 0.29%.

Prior to today's trading, shares of the hospital operator had gained 19.4% outpaced the Medical sector's gain of 5.6% and the S&P 500's gain of 2.2%.

Investors will be eagerly watching for the performance of Tenet Healthcare in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on July 24, 2026. The company's upcoming EPS is projected at $4.08, signifying a 1.49% increase compared to the same quarter of the previous year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $5.39 billion, up 2.27% from the year-ago period.

In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $17.61 per share and a revenue of $22.02 billion, indicating changes of +4.95% and +3.32%, respectively, from the former year.

Investors might also notice recent changes to analyst estimates for Tenet Healthcare. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.

Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.

Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. Tenet Healthcare is holding a Zacks Rank of #2 (Buy) right now.

With respect to valuation, Tenet Healthcare is currently being traded at a Forward P/E ratio of 11.74. This expresses no noticeable deviation compared to the average Forward P/E of 11.74 of its industry.

It is also worth noting that THC currently has a PEG ratio of 1.7. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The Medical - Hospital industry had an average PEG ratio of 1.7 as trading concluded yesterday.

The Medical - Hospital industry is part of the Medical sector. With its current Zacks Industry Rank of 60, this industry ranks in the top 25% of all industries, numbering over 250.

The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.

Tenet Healthcare (THC - Free Report) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

Over the past month, shares of this hospital operator have returned +25.2%, compared to the Zacks S&P 500 composite's +1.1% change. During this period, the Zacks Medical - Hospital industry, which Tenet falls in, has gained 20.1%. The key question now is: What could be the stock's future direction?

While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to an immediate price change, there are always some fundamental facts that eventually dominate the buy-and-hold decision-making.

Earnings Estimate RevisionsRather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.

Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements.

Tenet is expected to post earnings of $4.08 per share for the current quarter, representing a year-over-year change of +1.5%. Over the last 30 days, the Zacks Consensus Estimate remained unchanged.

The consensus earnings estimate of $17.61 for the current fiscal year indicates a year-over-year change of +5%. This estimate has remained unchanged over the last 30 days.

For the next fiscal year, the consensus earnings estimate of $17.63 indicates a change of +0.2% from what Tenet is expected to report a year ago. Over the past month, the estimate has remained unchanged.

Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Tenet is rated Zacks Rank #2 (Buy).

The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:

12 Month EPS

Revenue Growth ForecastWhile earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a company to increase its earnings for an extended period without increasing its revenues. So, it's important to know a company's potential revenue growth.

In the case of Tenet, the consensus sales estimate of $5.39 billion for the current quarter points to a year-over-year change of +2.3%. The $22.02 billion and $22.43 billion estimates for the current and next fiscal years indicate changes of +3.3% and +1.9%, respectively.

Last Reported Results and Surprise HistoryTenet reported revenues of $5.37 billion in the last reported quarter, representing a year-over-year change of +2.8%. EPS of $4.82 for the same period compares with $4.36 a year ago.

Compared to the Zacks Consensus Estimate of $5.39 billion, the reported revenues represent a surprise of -0.36%. The EPS surprise was +14.49%.

The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates three times over this period.

ValuationWithout considering a stock's valuation, no investment decision can be efficient. In predicting a stock's future price performance, it's crucial to determine whether its current price correctly reflects the intrinsic value of the underlying business and the company's growth prospects.

Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.

As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.

Tenet is graded A on this front, indicating that it is trading at a discount to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.

ConclusionThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Tenet. However, its Zacks Rank #2 does suggest that it may outperform the broader market in the near term.

Key Takeaways Tenet Healthcare is benefiting from rising adjusted admissions and strong Ambulatory Care growth.THC's earnings estimates moved higher, with projected 5% EPS growth and four straight earnings beats.Tenet Healthcare faces rising operating expenses despite cost-control efforts, posing a margin risk. Tenet Healthcare Corporation (THC - Free Report) is well-poised to grow, backed by the expanding adjusted admissions. Its solid Ambulatory Care segment performance is also a major tailwind. In the year-to-date period, shares of Tenet Healthcare have gained 2.6% against the industry’s 5.5% fall. Headquartered in Dallas, TX, THC operates as a provider of diversified healthcare services and has a market cap of $17.5 billion.

Driven by its solid prospects, this Zacks Rank #2 (Buy) stock is worth adding to your portfolio at the moment.

Let’s delve deeper.

The Zacks Consensus Estimate for Tenet Healthcare’s current-year earnings is pegged at $17.61 per share, which has witnessed two upward estimate revisions in the past 60 days against none in the opposite direction. The estimate indicates 5% year-over-year growth. Tenet Healthcare beat on earnings in all the last four quarters, with an average surprise of 20.6%.

The consensus mark for current-year revenues is pegged at $22.02 billion, signaling a 3.3% increase from a year ago. The company’s solid organic growth, supported by rising patient revenue per adjusted admission and a favorable shift toward higher-acuity services, is likely to support the top line. Favorable demographic trends, such as an aging population and rising chronic disease prevalence, are expected to sustain volume growth and support long-term revenue and earnings expansion.

THC's performance is benefiting from strong growth in its Ambulatory Care segment, driven by same-facility revenue gains, tuck-in acquisitions of ambulatory surgery centers and surgical hospitals, and continued expansion of the USPI platform. It had interests in 541 ambulatory surgery centers and 26 surgical hospitals in 37 states as of March 31, 2026. Ambulatory net operating revenues increased 17.3% in 2024, 14.1% in 2025 and 10.6% year over year in the first quarter of 2026.

THC's return on assets of 5.15% is higher than the industry average of 4.24%, indicating that the company is generating superior returns from its asset base, reflecting stronger operational efficiency and effective capital deployment compared with its peers.

Key Risk to MonitorHowever, investors should keep an eye on the company's expense profile. While Tenet Healthcare has implemented cost-control initiatives, including workforce optimization and renegotiated supplier and vendor contracts, expenses have continued to rise. Operating expenses increased 20.6% in 2025 and a further 4.6% year over year in the first quarter of 2026. Total expenses also rose as a percentage of sales. Persistent labor cost pressures, inflation in medical supplies and other inputs, and higher patient acuity are expected to keep expenses elevated, potentially weighing on margins.

Other Key PicksSome other top-ranked stocks in the broader Medical space are CVS Health Corporation (CVS - Free Report) , agilon health, inc. (AGL - Free Report) and Biodesix, Inc. (BDSX - Free Report) , each carrying a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

The Zacks Consensus Estimate for CVS Health’s 2026 bottom line suggests 10.2% year-over-year growth. CVS has witnessed 12 upward estimate revisions over the past 60 days against no movement in the opposite direction. It beat earnings estimates in all the last four quarters, with an average surprise of 16.8%.

The Zacks Consensus Estimate for agilon health’s full-year 2026 earnings indicates a 92.4% year-over-year improvement. AGL has witnessed two upward estimate revisions over the past 60 days against no movement in the opposite direction. The consensus mark for current-year revenues is currently pegged at $5.72 billion.

The Zacks Consensus Estimate for Biodesix’s 2026 full-year earnings implies a 37.7% improvement from the year-ago reported figure. BDSX beat earnings estimates in three of the last four quarters and missed once, with an average surprise of 25.6%. The consensus mark for its current-year revenues is pegged at $110.95 million, which indicates a 25.4% year-over-year increase.

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.

Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.

Zacks Premium includes access to the Zacks Style Scores as well.

What are the Zacks Style Scores? The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.

Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is better than a C, and so on.

The Style Scores are broken down into four categories:

Value ScoreFor value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks.

Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.

Momentum ScoreMomentum trading is all about taking advantage of upward or downward trends in a stock's price or earnings outlook, and these investors live by the saying "the trend is your friend." The Momentum Style Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates.

VGM ScoreIf you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.

How Style Scores Work with the Zacks Rank The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.

It's highly successful, with #1 (Strong Buy) stocks producing an unmatched +23.94% average annual return since 1988. That's more than double the S&P 500. But because of the large number of stocks we rate, there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.

With more than 800 top-rated stocks to choose from, it can certainly feel overwhelming to pick the ones that are right for you and your investing journey.

That's where the Style Scores come in.

To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.

The direction of a stock's earnings estimate revisions should always be a key factor when choosing which stocks to buy, since the Scores were created to work together with the Zacks Rank.

A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: Tenet Healthcare (THC - Free Report) Founded in 1967 and headquartered in Dallas, TX, Tenet Healthcare Corp., is an investor-owned health care services company, which owns and operates general hospitals and related health care facilities for urban and rural communities in numerous states, and has offices in California and Florida. The company has investments in other health care companies and is one of the largest investor-owned health care delivery systems in the United States.

THC is a #2 (Buy) on the Zacks Rank, with a VGM Score of A.

Additionally, the company could be a top pick for growth investors. THC has a Growth Style Score of A, forecasting year-over-year earnings growth of 5% for the current fiscal year.

Two analysts revised their earnings estimate upwards in the last 60 days for fiscal 2026. The Zacks Consensus Estimate has increased $0.12 to $17.61 per share. THC boasts an average earnings surprise of +20.6%.

With a solid Zacks Rank and top-tier Growth and VGM Style Scores, THC should be on investors' short list.

Stock market volatility is heating up, as investors digest cooler-than-anticipated nonfarm payrolls for June. A total of 57,000 jobs were added, notably below expectations of 115,000 while unemployment fell to 4.2%.The Dow Jones Industrial Average (DJI) is up triple digits as rate-hike worries ease, earlier tapping a fresh record high. The S&P 500 Index (SPX) sits flat, however, while the Nasdaq Composite Index (IXIC) pivots into the red thanks to weakness among semiconductors, memory stocks, and Tesla (TSLA). All three indexes are pacing for healthy weekly wins.

Continue reading for more on today's market, including:

Analyst: software stock still hasn't hit its top. 16 stocks ripe for a July short squeeze. Plus, Incyte options pop; two of the best and worst NYSE performers today.

Options traders are surrounding Incyte Corp (NYSE:INCY) today, continuing its recent run higher on the back of several drug approvals and a government settlement that secured funding of $246 million. INCY earlier tapped a roughly nine-year peak of $118.69 and is up 19% for 2026. So far 7,551 puts have crossed the tape, 80 times the average intraday rate. Most popular are the September 100 and 110 puts, where opening activity is present.

Healthcare giant Tenet Healthcare Corp (NYSE:THC) is near the top of the New York Stock Exchange (NYSE), last seen up 7.2% at $205, after Cantor Fitzgerald reiterated its "overweight" rating and $245 price target, citing undervaluation. Today's surge has the shares breaking above the $200 level, its year-to-date breakeven mark, and the 120-day moving average.

Fabrinet (NYSE:FN) is pacing the bottom of the NYSE, last seen down 6.8% at $510.02, extending its pullback from its mid-May highs. FN has struggled amid AI data center profit taking, with the tech pullback pressuring the shares back to levels not seen since early April. FN remains 12% higher for 2026.

Key Takeaways Tenet Healthcare's USPI delivered 6.1% adjusted EBITDA growth despite weather-related disruptions. THC invested $125M in seven ASC acquisitions and three de novo centers, nearing half its annual plan. Tenet Healthcare says higher-acuity outpatient procedures are strengthening growth and profitability. The next phase of Tenet Healthcare Corporation’s (THC - Free Report) growth is increasingly unfolding beyond its hospitals. Through United Surgical Partners International (“USPI”), Tenet is expanding its ambulatory surgery center (ASC) network to benefit from the healthcare industry's steady shift toward lower-cost outpatient care. As higher-acuity procedures continue shifting to outpatient settings, USPI is becoming an increasingly important driver of long-term growth.

That strategy is already translating into strong results. In the first quarter of 2026, USPI generated $484 million in adjusted EBITDA, up 6.1% year over year, while same-facility revenues increased 5.3%. The business also posted double-digit growth in outpatient joint replacements, reflecting rising demand for higher-acuity procedures. Despite weather-related disruptions, USPI delivered a stronger-than-expected quarter, underscoring the strength of the business.

Tenet is backing that momentum with continued investment. It invested $125 million during the quarter to acquire seven ASCs and open three de novo centers, completing nearly half of its planned annual investment. A healthy acquisition pipeline, coupled with reaffirmed full-year guidance, reflects confidence in USPI's long-term growth trajectory.

More importantly, USPI is helping reshape Tenet's portfolio. By expanding higher-acuity outpatient services, the company enables more complex procedures to be performed in lower-cost settings, supporting long-term growth and profitability. As the shift toward outpatient care continues, USPI is well positioned to remain a key driver of Tenet's long-term growth and shareholder value.

How Do Peers Compare?Tenet is not alone in capitalizing on the shift toward outpatient care. Medical peers such as Surgery Partners, Inc. (SGRY - Free Report) and HCA Healthcare, Inc. (HCA - Free Report) are also expanding their outpatient surgery networks to meet growing demand for lower-cost, high-quality surgical care.

Surgery Partners continues to expand its ambulatory surgery center network through acquisitions, physician partnerships and a growing focus on higher-acuity procedures. SGRY's strategy reflects the increasing demand for outpatient surgical care and reinforces the long-term growth potential of the ASC market.

HCA Healthcare continues investing in ambulatory surgery centers and outpatient facilities while expanding higher-acuity service lines. HCA is also increasing capacity across its outpatient network to support future patient demand and long-term growth.

THC’s Price Performance, Valuation & EstimatesShares of Tenet Healthcare have gained 8.6% over the past year compared to the industry's 4.3% decline over the same period.

Image Source: Zacks Investment Research

From a valuation standpoint, THC trades at a forward price-to-earnings ratio of 10.62X, up from the industry average of 9.06X. THCcarries a Value Score of A.

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for THC’s 2026 earnings is pegged at $17.61 per share, implying a 4.9% jump from the year-ago period’s level.

Image Source: Zacks Investment Research

THC currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

-

DALLAS--(BUSINESS WIRE)--Tenet Healthcare Corporation (NYSE: THC) will release its second quarter 2026 results before the market opens on Friday, July 24, 2026, to be followed by a conference call at 10:30 a.m. CT (11:30 a.m. Eastern Time).

A live webcast and audio archive of the call may be accessed through the investor relations section of Tenet’s website at www.tenethealth.com/investors.

About Tenet Healthcare

Tenet Healthcare Corporation (NYSE: THC) is a diversified healthcare services company headquartered in Dallas. Our care delivery network includes United Surgical Partners International, the largest ambulatory platform in the country, which operates ambulatory surgery centers and surgical hospitals. We also operate a national portfolio of acute care and specialty hospitals, other outpatient facilities, a network of leading employed physicians and a global business center in Manila, Philippines. Our Conifer Health Solutions subsidiary provides revenue cycle management and value-based care services to hospitals, health systems, physician practices, employers, and other clients. Across the Tenet enterprise, we are united by our mission to deliver quality, compassionate care in the communities we serve. For more information, please visit www.tenethealth.com.

More News From Tenet Healthcare Corporation

Back to Newsroom

Tenet Healthcare (THC - Free Report) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

Over the past month, shares of this hospital operator have returned -4.8%, compared to the Zacks S&P 500 composite's +0.3% change. During this period, the Zacks Medical - Hospital industry, which Tenet falls in, has lost 11.4%. The key question now is: What could be the stock's future direction?

Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.

Earnings Estimate RevisionsRather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.

We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

Tenet is expected to post earnings of $4.08 per share for the current quarter, representing a year-over-year change of +1.5%. Over the last 30 days, the Zacks Consensus Estimate has changed -0.7%.

The consensus earnings estimate of $17.61 for the current fiscal year indicates a year-over-year change of +5%. This estimate has changed +0.2% over the last 30 days.

For the next fiscal year, the consensus earnings estimate of $17.63 indicates a change of +0.2% from what Tenet is expected to report a year ago. Over the past month, the estimate has remained unchanged.

With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #2 (Buy) for Tenet.

The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:

12 Month EPS

Projected Revenue GrowthEven though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.

For Tenet, the consensus sales estimate for the current quarter of $5.39 billion indicates a year-over-year change of +2.3%. For the current and next fiscal years, $22.02 billion and $22.43 billion estimates indicate +3.3% and +1.9% changes, respectively.

Last Reported Results and Surprise HistoryTenet reported revenues of $5.37 billion in the last reported quarter, representing a year-over-year change of +2.8%. EPS of $4.82 for the same period compares with $4.36 a year ago.

Compared to the Zacks Consensus Estimate of $5.39 billion, the reported revenues represent a surprise of -0.36%. The EPS surprise was +14.49%.

The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates three times over this period.

ValuationWithout considering a stock's valuation, no investment decision can be efficient. In predicting a stock's future price performance, it's crucial to determine whether its current price correctly reflects the intrinsic value of the underlying business and the company's growth prospects.

Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.

As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.

Tenet is graded A on this front, indicating that it is trading at a discount to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.

ConclusionThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Tenet. However, its Zacks Rank #2 does suggest that it may outperform the broader market in the near term.

Tenet Healthcare (THC - Free Report) ended the recent trading session at $179.11, demonstrating a +2.55% change from the preceding day's closing price. The stock outperformed the S&P 500, which registered a daily gain of 1.65%. Meanwhile, the Dow gained 0.92%, and the Nasdaq, a tech-heavy index, added 3.07%.

The hospital operator's shares have seen a decrease of 11.19% over the last month, not keeping up with the Medical sector's gain of 3.59% and the S&P 500's gain of 0.48%.

Investors will be eagerly watching for the performance of Tenet Healthcare in its upcoming earnings disclosure. In that report, analysts expect Tenet Healthcare to post earnings of $4.08 per share. This would mark year-over-year growth of 1.49%. Alongside, our most recent consensus estimate is anticipating revenue of $5.39 billion, indicating a 2.27% upward movement from the same quarter last year.

Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $17.61 per share and revenue of $22.02 billion. These totals would mark changes of +4.95% and +3.32%, respectively, from last year.

Investors should also take note of any recent adjustments to analyst estimates for Tenet Healthcare. These recent revisions tend to reflect the evolving nature of short-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.

Our research shows that these estimate changes are directly correlated with near-term stock prices. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.

The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.67% upward. Tenet Healthcare presently features a Zacks Rank of #2 (Buy).

From a valuation perspective, Tenet Healthcare is currently exchanging hands at a Forward P/E ratio of 9.92. Its industry sports an average Forward P/E of 9.92, so one might conclude that Tenet Healthcare is trading at no noticeable deviation comparatively.

It's also important to note that THC currently trades at a PEG ratio of 1.44. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. Medical - Hospital stocks are, on average, holding a PEG ratio of 1.44 based on yesterday's closing prices.

The Medical - Hospital industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 108, finds itself in the top 45% echelons of all 250+ industries.

The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

To follow THC in the coming trading sessions, be sure to utilize Zacks.com.

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.

Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.

Zacks Premium includes access to the Zacks Style Scores as well.

What are the Zacks Style Scores? The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.

Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.

The Style Scores are broken down into four categories:

Value ScoreValue investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and many other multiples, the Value Style Score identifies the most attractive and most discounted stocks.

Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.

Momentum ScoreMomentum trading is all about taking advantage of upward or downward trends in a stock's price or earnings outlook, and these investors live by the saying "the trend is your friend." The Momentum Style Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates.

VGM ScoreIf you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.

How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.

Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +24% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.

This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.

That's where the Style Scores come in.

To have the best chance of big returns, you'll want to always consider stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B, which will give you the highest probability of success. If you're looking at stocks with a #3 (Hold) rank, it's important they have Scores of A or B as well to ensure as much upside potential as possible.

Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.

A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: Tenet Healthcare (THC - Free Report) Founded in 1967 and headquartered in Dallas, TX, Tenet Healthcare Corp., is an investor-owned health care services company, which owns and operates general hospitals and related health care facilities for urban and rural communities in numerous states, and has offices in California and Florida. The company has investments in other health care companies and is one of the largest investor-owned health care delivery systems in the United States.

THC is a #3 (Hold) on the Zacks Rank, with a VGM Score of A.

It also boasts a Value Style Score of A thanks to attractive valuation metrics like a forward P/E ratio of 9.84; value investors should take notice.

Eight analysts revised their earnings estimate upwards in the last 60 days for fiscal 2026. The Zacks Consensus Estimate has increased $0.42 to $17.61 per share. THC boasts an average earnings surprise of +20.6%.

With a solid Zacks Rank and top-tier Value and VGM Style Scores, THC should be on investors' short list.

Tenet Healthcare (THC - Free Report) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.

Shares of this hospital operator have returned -4% over the past month versus the Zacks S&P 500 composite's +9.5% change. The Zacks Medical - Hospital industry, to which Tenet belongs, has lost 2.4% over this period. Now the key question is: Where could the stock be headed in the near term?

Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.

Earnings Estimate RevisionsHere at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock.

We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

For the current quarter, Tenet is expected to post earnings of $4.15 per share, indicating a change of +3.2% from the year-ago quarter. The Zacks Consensus Estimate has changed -2.1% over the last 30 days.

For the current fiscal year, the consensus earnings estimate of $17.56 points to a change of +4.7% from the prior year. Over the last 30 days, this estimate has changed +1.5%.

For the next fiscal year, the consensus earnings estimate of $17.58 indicates a change of +0.1% from what Tenet is expected to report a year ago. Over the past month, the estimate has changed +1%.

Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Tenet is rated Zacks Rank #2 (Buy).

The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:

12 Month EPS

Projected Revenue GrowthWhile earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a company to increase its earnings for an extended period without increasing its revenues. So, it's important to know a company's potential revenue growth.

In the case of Tenet, the consensus sales estimate of $5.42 billion for the current quarter points to a year-over-year change of +2.8%. The $21.98 billion and $22.41 billion estimates for the current and next fiscal years indicate changes of +3.1% and +1.9%, respectively.

Last Reported Results and Surprise HistoryTenet reported revenues of $5.37 billion in the last reported quarter, representing a year-over-year change of +2.8%. EPS of $4.82 for the same period compares with $4.36 a year ago.

Compared to the Zacks Consensus Estimate of $5.39 billion, the reported revenues represent a surprise of -0.36%. The EPS surprise was +14.49%.

The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates three times over this period.

ValuationNo investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.

While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.

As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.

Tenet is graded A on this front, indicating that it is trading at a discount to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.

ConclusionThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Tenet. However, its Zacks Rank #2 does suggest that it may outperform the broader market in the near term.

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.

Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.

Zacks Premium includes access to the Zacks Style Scores as well.

What are the Zacks Style Scores? The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.

Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.

The Style Scores are broken down into four categories:

Value ScoreFinding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.

Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.

Momentum ScoreMomentum trading is all about taking advantage of upward or downward trends in a stock's price or earnings outlook, and these investors live by the saying "the trend is your friend." The Momentum Style Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates.

VGM ScoreIf you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.

How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.

Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +23.7% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.

But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.

That's where the Style Scores come in.

To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.

Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.

A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: Tenet Healthcare (THC - Free Report) Founded in 1967 and headquartered in Dallas, TX, Tenet Healthcare Corp., is an investor-owned health care services company, which owns and operates general hospitals and related health care facilities for urban and rural communities in numerous states, and has offices in California and Florida. The company has investments in other health care companies and is one of the largest investor-owned health care delivery systems in the United States.

THC is a #2 (Buy) on the Zacks Rank, with a VGM Score of A.

It also boasts a Value Style Score of A thanks to attractive valuation metrics like a forward P/E ratio of 11.05; value investors should take notice.

For fiscal 2026, seven analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.66 to $17.56 per share. THC boasts an average earnings surprise of +20.6%.

With a solid Zacks Rank and top-tier Value and VGM Style Scores, THC should be on investors' short list.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Considering these trends, value investing is clearly one of the most preferred ways to find strong stocks in any type of market. Value investors rely on traditional forms of analysis on key valuation metrics to find stocks that they believe are undervalued, leaving room for profits.

In addition to the Zacks Rank, investors looking for stocks with specific traits can utilize our Style Scores system. Of course, value investors will be most interested in the system's "Value" category. Stocks with "A" grades for Value and high Zacks Ranks are among the best value stocks available at any given moment.

One company value investors might notice is Tenet Healthcare (THC - Free Report) . THC is currently sporting a Zacks Rank #2 (Buy), as well as an A grade for Value.

We also note that THC holds a PEG ratio of 0.81. This popular figure is similar to the widely-used P/E ratio, but the PEG ratio also considers a company's expected EPS growth rate. THC's industry currently sports an average PEG of 1.60. Over the past 52 weeks, THC's PEG has been as high as 1.30 and as low as 0.55, with a median of 0.81.

Finally, investors will want to recognize that THC has a P/CF ratio of 7.51. This data point considers a firm's operating cash flow and is frequently used to find companies that are undervalued when considering their solid cash outlook. THC's current P/CF looks attractive when compared to its industry's average P/CF of 7.65. Over the past 52 weeks, THC's P/CF has been as high as 7.76 and as low as 2.83, with a median of 4.42.

These figures are just a handful of the metrics value investors tend to look at, but they help show that Tenet Healthcare is likely being undervalued right now. Considering this, as well as the strength of its earnings outlook, THC feels like a great value stock at the moment.

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Let's take a look at what these Wall Street heavyweights have to say about Tenet Healthcare (THC - Free Report) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.

Tenet currently has an average brokerage recommendation (ABR) of 1.39, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 22 brokerage firms. An ABR of 1.39 approximates between Strong Buy and Buy.

Of the 22 recommendations that derive the current ABR, 16 are Strong Buy and three are Buy. Strong Buy and Buy respectively account for 72.7% and 13.6% of all recommendations.

Brokerage Recommendation Trends for THC

Check price target & stock forecast for Tenet here>>>

The ABR suggests buying Tenet, but making an investment decision solely on the basis of this information might not be a good idea. According to several studies, brokerage recommendations have little to no success guiding investors to choose stocks with the most potential for price appreciation.

Are you wondering why? The vested interest of brokerage firms in a stock they cover often results in a strong positive bias of their analysts in rating it. Our research shows that for every "Strong Sell" recommendation, brokerage firms assign five "Strong Buy" recommendations.

This means that the interests of these institutions are not always aligned with those of retail investors, giving little insight into the direction of a stock's future price movement. It would therefore be best to use this information to validate your own analysis or a tool that has proven to be highly effective at predicting stock price movements.

Zacks Rank, our proprietary stock rating tool with an impressive externally audited track record, categorizes stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), and is an effective indicator of a stock's price performance in the near future. Therefore, using the ABR to validate the Zacks Rank could be an efficient way of making a profitable investment decision.

ABR Should Not Be Confused With Zacks RankAlthough both Zacks Rank and ABR are displayed in a range of 1--5, they are different measures altogether.

Broker recommendations are the sole basis for calculating the ABR, which is typically displayed in decimals (such as 1.28). The Zacks Rank, on the other hand, is a quantitative model designed to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.

It has been and continues to be the case that analysts employed by brokerage firms are overly optimistic with their recommendations. Because of their employers' vested interests, these analysts issue more favorable ratings than their research would support, misguiding investors far more often than helping them.

On the other hand, earnings estimate revisions are at the core of the Zacks Rank. And empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

Furthermore, the different grades of the Zacks Rank are applied proportionately across all stocks for which brokerage analysts provide earnings estimates for the current year. In other words, at all times, this tool maintains a balance among the five ranks it assigns.

Another key difference between the ABR and Zacks Rank is freshness. The ABR is not necessarily up-to-date when you look at it. But, since brokerage analysts keep revising their earnings estimates to account for a company's changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in indicating future price movements.

Should You Invest in THC?Looking at the earnings estimate revisions for Tenet, the Zacks Consensus Estimate for the current year has increased 2% over the past month to $17.64.

Analysts' growing optimism over the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher, could be a legitimate reason for the stock to soar in the near term.

The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #2 (Buy) for Tenet. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

Therefore, the Buy-equivalent ABR for Tenet may serve as a useful guide for investors.

Tenet Healthcare (THC - Free Report) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.

Shares of this hospital operator have returned -2% over the past month versus the Zacks S&P 500 composite's +4.6% change. The Zacks Medical - Hospital industry, to which Tenet belongs, has lost 5.5% over this period. Now the key question is: Where could the stock be headed in the near term?

Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.

Revisions to Earnings EstimatesHere at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock.

We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

For the current quarter, Tenet is expected to post earnings of $4.15 per share, indicating a change of +3.2% from the year-ago quarter. The Zacks Consensus Estimate has changed -2.1% over the last 30 days.

The consensus earnings estimate of $17.64 for the current fiscal year indicates a year-over-year change of +5.1%. This estimate has changed +2% over the last 30 days.

For the next fiscal year, the consensus earnings estimate of $17.66 indicates a change of +0.1% from what Tenet is expected to report a year ago. Over the past month, the estimate has changed +1.4%.

Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Tenet is rated Zacks Rank #3 (Hold).

The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:

12 Month EPS

Revenue Growth ForecastEven though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.

In the case of Tenet, the consensus sales estimate of $5.41 billion for the current quarter points to a year-over-year change of +2.6%. The $22.02 billion and $22.37 billion estimates for the current and next fiscal years indicate changes of +3.4% and +1.6%, respectively.

Last Reported Results and Surprise HistoryTenet reported revenues of $5.37 billion in the last reported quarter, representing a year-over-year change of +2.8%. EPS of $4.82 for the same period compares with $4.36 a year ago.

Compared to the Zacks Consensus Estimate of $5.39 billion, the reported revenues represent a surprise of -0.36%. The EPS surprise was +14.49%.

The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates three times over this period.

ValuationNo investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.

Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.

The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an A is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.

Tenet is graded A on this front, indicating that it is trading at a discount to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.

Bottom LineThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Tenet. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.

Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. However, it isn't easy to find a great growth stock.

In addition to volatility, these stocks carry above-average risk by their very nature. Also, one could end up losing from a stock whose growth story is actually over or nearing its end.

However, the task of finding cutting-edge growth stocks is made easy with the help of the Zacks Growth Style Score (part of the Zacks Style Scores system), which looks beyond the traditional growth attributes to analyze a company's real growth prospects.

Tenet Healthcare (THC - Free Report) is one such stock that our proprietary system currently recommends. The company not only has a favorable Growth Score, but also carries a top Zacks Rank.

Studies have shown that stocks with the best growth features consistently outperform the market. And returns are even better for stocks that possess the combination of a Growth Score of A or B and a Zacks Rank #1 (Strong Buy) or 2 (Buy).

Here are three of the most important factors that make the stock of this hospital operator a great growth pick right now.

Earnings GrowthEarnings growth is arguably the most important factor, as stocks exhibiting exceptionally surging profit levels tend to attract the attention of most investors. And for growth investors, double-digit earnings growth is definitely preferable, and often an indication of strong prospects (and stock price gains) for the company under consideration.

While the historical EPS growth rate for Tenet is 24.8%, investors should actually focus on the projected growth. The company's EPS is expected to grow 5.3% this year, crushing the industry average, which calls for EPS growth of -10.2%.

Cash Flow GrowthCash is the lifeblood of any business, but higher-than-average cash flow growth is more beneficial and important for growth-oriented companies than for mature companies. That's because, high cash accumulation enables these companies to undertake new projects without raising expensive outside funds.

Right now, year-over-year cash flow growth for Tenet is 20.1%, which is higher than many of its peers. In fact, the rate compares to the industry average of 17.9%.

While investors should actually consider the current cash flow growth, it's worth taking a look at the historical rate too for putting the current reading into proper perspective. The company's annualized cash flow growth rate has been 11.5% over the past 3-5 years versus the industry average of 3.9%.

Promising Earnings Estimate RevisionsSuperiority of a stock in terms of the metrics outlined above can be further validated by looking at the trend in earnings estimate revisions. A positive trend is of course favorable here. Empirical research shows that there is a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

There have been upward revisions in current-year earnings estimates for Tenet. The Zacks Consensus Estimate for the current year has surged 2.2% over the past month.

Bottom LineTenet has not only earned a Growth Score of A based on a number of factors, including the ones discussed above, but it also carries a Zacks Rank #2 because of the positive earnings estimate revisions.

You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

This combination positions Tenet well for outperformance, so growth investors may want to bet on it.

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.

The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.

Zacks Premium includes access to the Zacks Style Scores as well.

What are the Zacks Style Scores? The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.

Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is better than a C, and so on.

The Style Scores are broken down into four categories:

Value ScoreFinding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.

Growth ScoreWhile good value is important, growth investors are more focused on a company's financial strength and health, and its future outlook. The Growth Style Score takes projected and historic earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.

Momentum ScoreMomentum investors, who live by the saying "the trend is your friend," are most interested in taking advantage of upward or downward trends in a stock's price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks.

VGM ScoreIf you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.

How Style Scores Work with the Zacks Rank The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier.

It's highly successful, with #1 (Strong Buy) stocks producing an unmatched +23.7% average annual return since 1988. That's more than double the S&P 500. But because of the large number of stocks we rate, there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.

This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.

That's where the Style Scores come in.

To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.

As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.

For instance, a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one that boasts Scores of A and B, still has a downward-trending earnings forecast, and a much greater likelihood its share price will decline as well.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: Tenet Healthcare (THC - Free Report) Founded in 1967 and headquartered in Dallas, TX, Tenet Healthcare Corp., is an investor-owned health care services company, which owns and operates general hospitals and related health care facilities for urban and rural communities in numerous states, and has offices in California and Florida. The company has investments in other health care companies and is one of the largest investor-owned health care delivery systems in the United States.

THC is a #2 (Buy) on the Zacks Rank, with a VGM Score of A.

Additionally, the company could be a top pick for growth investors. THC has a Growth Style Score of A, forecasting year-over-year earnings growth of 5.3% for the current fiscal year.

For fiscal 2026, eight analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.37 to $17.67 per share. THC boasts an average earnings surprise of +20.6%.

With a solid Zacks Rank and top-tier Growth and VGM Style Scores, THC should be on investors' short list.

Tenet Healthcare (THC - Free Report) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.

Shares of this hospital operator have returned -15.3% over the past month versus the Zacks S&P 500 composite's +4.6% change. The Zacks Medical - Hospital industry, to which Tenet belongs, has lost 10.7% over this period. Now the key question is: Where could the stock be headed in the near term?

Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.

Earnings Estimate RevisionsHere at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock.

We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

For the current quarter, Tenet is expected to post earnings of $4.08 per share, indicating a change of +1.5% from the year-ago quarter. The Zacks Consensus Estimate has changed -0.6% over the last 30 days.

For the current fiscal year, the consensus earnings estimate of $17.61 points to a change of +5% from the prior year. Over the last 30 days, this estimate has changed +0.6%.

For the next fiscal year, the consensus earnings estimate of $17.63 indicates a change of +0.2% from what Tenet is expected to report a year ago. Over the past month, the estimate has changed +0.5%.

Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Tenet is rated Zacks Rank #3 (Hold).

The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:

12 Month EPS

Projected Revenue GrowthWhile earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a company to increase its earnings for an extended period without increasing its revenues. So, it's important to know a company's potential revenue growth.

For Tenet, the consensus sales estimate for the current quarter of $5.39 billion indicates a year-over-year change of +2.3%. For the current and next fiscal years, $22.02 billion and $22.43 billion estimates indicate +3.3% and +1.9% changes, respectively.

Last Reported Results and Surprise HistoryTenet reported revenues of $5.37 billion in the last reported quarter, representing a year-over-year change of +2.8%. EPS of $4.82 for the same period compares with $4.36 a year ago.

Compared to the Zacks Consensus Estimate of $5.39 billion, the reported revenues represent a surprise of -0.36%. The EPS surprise was +14.49%.

The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates three times over this period.

ValuationNo investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.

Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.

The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an A is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.

Tenet is graded A on this front, indicating that it is trading at a discount to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.

ConclusionThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Tenet. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.